Targeting Mitochondrial Metabolism Shows Promise in Pancreatic Cancer
Researchers report promising results from a phase I trial evaluating CPI-613, which targets mitochondrial metabolism, in combination with modified FOLFIRINOX chemotherapy for the treatment of metastatic pancreatic cancer.
They say: “This study provides encouraging evidence for a novel, potentially effective combination chemotherapy regimen […] that was safe and well tolerated in patients with metastatic pancreatic cancer.” Read more . . .